PREDNISOLONE ENCAPSULATED SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLES FOR TARGET DRUG DELIVERY – DESIGN AND QUANTIFICATION

Objective: The present study aimed to develop a novel type of superparamagnetic iron oxide nanoparticles (SPIONs) to deliver prednisolone at colon as a target site for the treatment of inflammatory bowel disease (IBD) such as ulcerative colitis and Crohn’s disease which may further progress to cance...

Full description

Saved in:
Bibliographic Details
Published in:Asian journal of pharmaceutical and clinical research pp. 126 - 131
Main Authors: SUBASHINI RAJARAM, SENTHIL RAJAN DHARMALINGAM, SANTHOSE RANI A, SAPTHASRI R, VARSHA D, VINODHINI V
Format: Journal Article
Language:English
Published: 27-09-2019
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective: The present study aimed to develop a novel type of superparamagnetic iron oxide nanoparticles (SPIONs) to deliver prednisolone at colon as a target site for the treatment of inflammatory bowel disease (IBD) such as ulcerative colitis and Crohn’s disease which may further progress to cancer. Methods: SPIONs were synthesized using a coprecipitation method. Further, it was encapsulated with prednisolone-polyethylene glycol by double emulsion method (W1/O/W2). The prepared formulations were characterized for its physicochemical characterization such as scanning electron microscopy, X-ray diffraction, particle size and zeta potential, encapsulation efficiency, and in vitro drug release. Results: The results reveal that the physicochemical property of the formulations complies with the standard values and in vitro release of prednisolone in the first 18 h, attains 57 and 58% and it reaches 71 and 75% at 24 h, and this is statistically significant (p˂0.0177). This release result implies that the drug release from the formulations is controllable and sustains manner. Conclusion: Our findings could be a promising approach for the delivery of prednisolone with enhanced half-life for the treatment of IBD through colon targeting.
ISSN:0974-2441
0974-2441
DOI:10.22159/ajpcr.2019.v12i11.35439